# A Clinical Study Evaluating the Safety, Tolerability, and Efficacy of MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism

> **NCT06747247** · PHASE2 · COMPLETED · sponsor: **Shaanxi Micot Pharmaceutical Technology Co., Ltd.** · enrollment: 98 (actual)

## Conditions studied

- Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis

## Interventions

- **DRUG:** Long-term Dosing Cohort
- **DRUG:** Single ascending doses of MT1013
- **DRUG:** Multiple ascending doses of MT1013

## Key facts

- **NCT ID:** NCT06747247
- **Lead sponsor:** Shaanxi Micot Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-07
- **Primary completion:** 2025-05-12
- **Final completion:** 2025-05-12
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06747247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06747247, "A Clinical Study Evaluating the Safety, Tolerability, and Efficacy of MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06747247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*